NewsRx

Search our medical news database

Conference Coverage (CHI Vaccines)

Virus-Like Particle Vaccines for VZV, HIV, Malaria, Hepatitis, More

Published in Vaccine Weekly, April 1st, 1996

The versatile virus-like particle (VLP) produced by the yeast transposon promises to vastly improve particulate antigen vaccines.

Simple monomeric proteins are by themselves only poorly immunogenic. But the creation of particulate, polyvalent antigens permits the elicitation of immune responses without the risks posed by live attenuated pathogens.

In a presentation to the Cambridge Healthtech Institute's Vaccines: New Technologies and Applications conference, held March 18-20, 1996, in McLean, Virginia, researcher Guy Layton of British Biotech Pharmaceuticals Ltd., Oxford, England, summarized the advantages of particulate antigen...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook